Quick Answer
Viridian Therapeutics, Inc.DE reported Cash and Equivalents of $32.61 million for fiscal year 2018.
Viridian Therapeutics, Inc.DE Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2018 | $32.61M | -31.3% |
| 2017 | $47.44M | +114.6% |
| 2016 | $22.10M | +4.1% |
| 2015 | $21.23M | +314.8% |
| 2014 | $5.12M | +2349.3% |
| 2013 | $209.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2019 | $24.86M | -21.6% | +3.5% |
| June 30, 2019 | $24.01M | -44.7% | +31.9% |
| March 31, 2019 | $18.20M | -76.7% | -44.2% |
| December 31, 2018 | $32.61M | -31.3% | +2.9% |
| September 30, 2018 | $31.70M | -25.9% | -27.0% |
| June 30, 2018 | $43.40M | -6.3% | -44.4% |
| March 31, 2018 | $78.10M | +68.6% | +64.6% |
| December 31, 2017 | $47.44M | +114.6% | +10.8% |
- Viridian Therapeutics, Inc.DE showed a decrease of -31.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2018 period, Viridian Therapeutics, Inc.DE’s cash and equivalents has grown by 15501.0% (from $209.0 thousand to $32.61 million).
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2018 report (Form 10-K), filed with the SEC on March 14, 2019.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: